Hemophagocytic Lymphohistiocytosis Thought to Be due to Undifferentiated Connective Tissue Disease Treated With Ruxolitinib: A Case Report.
- 1Carle Illinois College of Medicine Urbana Illinois USA.
- 2Carle Foundation Hospital Urbana Illinois USA carle.org.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening, systemic inflammatory syndrome. Cases without an identifiable acquired trigger are referred to as secondary HLH. In this report, we describe the case of a 24 year-old woman whose underlying cause of HLH was particularly difficult to determine. Her condition was initially suspected to be due to lamotrigine use but is now thought to be a result of undifferentiated connective tissue disease. During the patient's prolonged and complex hospital stay, she received the diagnosis of secondary HLH. Discontinuing lamotrigine, a drug that rarely causes HLH, did not improve her condition. The patient was tested for infectious and malignant conditions with negative results. Further workup revealed a positive ANA and bilateral MCP tenosynovitis, with negative specific antibodies, suggesting an undefined rheumatologic process. A number of conventional therapies did not show clear benefit, including etoposide, high-dose steroids, rituximab, and plasmapheresis. The patient remained in critical condition until she began treatment with ruxolitinib, with which she remains stable more than 5 years later. Ruxolitinib has shown some success in treating HLH in preliminary studies, but it is still considered a salvage therapy. This case illustrates the successful use of ruxolitinib in a patient with HLH likely due to undifferentiated connective tissue disease.
Related
- Breaking the Storm: Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome as the First Manifestation of Systemic Lupus Erythematosus/Mixed Connective Tissue Disease in an Adolescent Successfully Treated With Anakinra.
- Commentary: Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management
- Hemophagocytic Lymphohistiocytosis in a Patient With Alcohol‐Associated Liver Disease: A Case Report Highlighting Diagnostic Challenges
- Hemophagocytic Lymphohistiocytosis as a Clinical Harbinger of Rapid Disease Progression in Multiple Myeloma During Daratumumab-Based Therapy
- An Active Cytomegalovirus Infection and Epstein-Barr Virus Reactivation Complicated by Cytomegalovirus Meningitis and Virus-Associated Hemophagocytic Lymphohistiocytosis during Methotrexate and Upadacitinib Therapy in a Patient with Rheumatoid Arthritis
BibTeX
@article{vachon2026hemophagocytic,
title = {{Hemophagocytic Lymphohistiocytosis Thought to Be due to Undifferentiated Connective Tissue Disease Treated With Ruxolitinib: A Case Report.}},
author = {Emily Vachon and Heena Birbal Jain and Suzanna Kitten},
journal = {Case reports in rheumatology},
year = {2026},
month = oct,
doi = {10.1155/crrh/9165820},
url = {https://europepmc.org/article/MED/42894865},
note = {CC BY},
}
RIS
TY - JOUR
TI - Hemophagocytic Lymphohistiocytosis Thought to Be due to Undifferentiated Connective Tissue Disease Treated With Ruxolitinib: A Case Report.
AU - Emily Vachon
AU - Heena Birbal Jain
AU - Suzanna Kitten
PY - 2026
DA - 2026/10/18
JO - Case reports in rheumatology
DO - 10.1155/crrh/9165820
UR - https://europepmc.org/article/MED/42894865
AB - Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening, systemic inflammatory syndrome. Cases without an identifiable acquired trigger are referred to as secondary HLH. In this report, we describe the case of a 24 year-old woman whose underlying cause of HLH was particularly difficult to determine. Her condition was initially suspected to be due to lamotrigine use but is now thought to be a result of undifferentiated connective tissue disease. During the patient's prolonged and complex hospital stay, she received the diagnosis of secondary HLH. Discontinuing lamotrigine, a drug that rarely causes HLH, did not improve her condition. The patient was tested for infectious and malignant conditions with negative results. Further workup revealed a positive ANA and bilateral MCP tenosynovitis, with negative specific antibodies, suggesting an undefined rheumatologic process. A number of conventional therapies did not show clear benefit, including etoposide, high-dose steroids, rituximab, and plasmapheresis. The patient remained in critical condition until she began treatment with ruxolitinib, with which she remains stable more than 5 years later. Ruxolitinib has shown some success in treating HLH in preliminary studies, but it is still considered a salvage therapy. This case illustrates the successful use of ruxolitinib in a patient with HLH likely due to undifferentiated connective tissue disease.
SN - 2090-6889
SN - 2090-6897
ER -